We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-5.74%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.49B
AUM Growth
-$345M
Cap. Flow
-$1.43B
Cap. Flow %
-31.97%
Top 10 Hldgs %
44.77%
Holding
117
New
16
Increased
17
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$76.9M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$73.8M
3
AHCO icon
AdaptHealth
AHCO
+$54.6M
4
ACH
Accendra Health
ACH
+$48.2M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$47.9M

Top Sells

Rank Stock Value
1
PHR icon
Phreesia
PHR
+$44.2M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$42M
3
IMGN
Immunogen Inc
IMGN
+$31.5M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$24.6M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 62.79%
2 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TOIIW
76
The Oncology Institute Warrant
TOIIW
$4.36M
$81.4K ﹤0.01%
1,250,000
– –
QSIAW
77
DELISTED
Quantum-Si Inc Warrant
QSIAW
$50K ﹤0.01%
333,333
– –
SLGCW
78
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$36K ﹤0.01%
120,000
– –
TLSIW icon
79
TriSalus Life Sciences Warrant
TLSIW
$28.4M
$20.5K ﹤0.01%
333,333
– –
NUVB.WS
80
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$20K ﹤0.01%
166,666
– –
SNRHW
81
DELISTED
Senior Connect Acquisition Corp. I Warrant
SNRHW
$19.6K ﹤0.01%
500,000
– –
SRZNW icon
82
Surrozen Inc Warrant
SRZNW
$75.6K
$16.7K ﹤0.01%
166,666
– –
SIEN
83
DELISTED
Sientra, Inc.
SIEN
$15.4K ﹤0.01%
10,000
-257,995
-96% -$458K
EUCRW
84
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$13.5K ﹤0.01%
333,333
– –
MTACU
85
DELISTED
MedTech Acquisition Corporation Unit
MTACU
$10 ﹤0.01%
1
– –
EUCRU
86
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$10 ﹤0.01%
1
– –
CALC icon
87
CalciMedica
CALC
$11.3M
– –
-377,265
Closed -$2.64M
DAWN
88
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-964,033
Closed -$20.7M
KZR
89
DELISTED
Kezar Life Sciences
KZR
– –
-143,000
Closed -$10.1M
PCRX icon
90
Pacira BioSciences
PCRX
$1.05B
– –
-292,000
Closed -$11.3M
PEPG icon
91
PepGen
PEPG
$127M
– –
-60,009
Closed -$802K
PHR icon
92
Phreesia
PHR
$671M
– –
-1,366,329
Closed -$44.2M
IMGN
93
DELISTED
Immunogen Inc
IMGN
– –
-6,358,314
Closed -$31.5M
ONCR
94
DELISTED
Oncorus, Inc.
ONCR
– –
-2,536,186
Closed -$642K
APEN
95
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-1,750,000
Closed -$17.4M
PKBOW
96
DELISTED
Peak Bio, Inc. Warrant
PKBOW
– –
-362,500
Closed -$73.4K
1 2 3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2023 Portfolio in Review

As of Q1 2023, Deerfield Management held 117 positions worth $4.49B, down 7.1% from $4.83B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Deerfield Management withdrew a net $1.43B in Q1 2023, closing 11 positions and reducing 12 holdings. Its most notable exit was Phreesia, an estimated $44.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 56% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intra-Cellular Therapies Inc. worth $39.7M.

  • Deerfield Management's largest Q1 2023 buy was Intra-Cellular Therapies Inc.: 734,000 shares worth $39.7M.
  • Deerfield Management added most to Viatris in Q1 2023, an estimated $76.9M increase.
  • Deerfield Management's biggest Q1 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $42M.
  • Deerfield Management fully exited Phreesia in Q1 2023, selling an estimated $44.2M.
  • Deerfield Management's ten largest holdings make up 45% of its $4.49B portfolio in Q1 2023.
  • Deerfield Management opened 16 new positions and closed 11 in Q1 2023.
  • Deerfield Management's portfolio value fell 7.1% quarter-over-quarter to $4.49B.

Based on Deerfield Management's 13F filing for Q1 2023, filed 15 May 2023.